Senate passes a “right to try” bill; Harm to patients comes next

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 
Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login